About
Develops a metabolomics-based diagnostic platform and markets a non-invasive laboratory-developed test (LDT) for diagnosing nonalcoholic steatohepatitis (NASH).
Explore OWL Metabolomics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.